Despite a rocky Q1 start to 2025 with a 4.3% market drop, AbbVie managed to thrive amid economic unease and shifting investor ...

Carillon Tower Advisers, an investment management company, released its “Carillon Eagle Growth & Income Fund” first quarter 2025 investor letter. A copy of the letter can be downloaded here. The S&P ...

Novavax received Food and Drug Administration approval for its new, protein-based COVID-19 vaccine, and shares jumped 25% at the opening bell Monday.

Supported by world-class markets data from Dow Jones and FactSet, and partnering with Automated Insights, MarketWatch ...

John Navin is a freelance writer for Investopedia. His stock-trading work was profiled in "The Warren Buffetts Next Door: The World's Greatest Investors You've Never Heard Of." Bloomberg/Getty ...

Calling AbbVie Inc. (NYSE:ABBV) one of his “absolute favorites” during the recent episode of Mad Money, Cramer said: “Or how ...

Citigroup has reiterated its neutral stance on AbbVie, nudging its price target down from $210 to $205, despite the company’s ...